Advice

Recommended for restricted use within NHS Scotland.

REASONS FOR ADVICE.

Pegylated interferon alfa-2a is an appropriate treatment for the treatment of adult patients with chronic hepatitis C under the overall supervision of specialists experienced in the management of this disorder. This treatment involves a weekly injection from a pre-filled syringe that reduces inconvenience to patients whilst increasing the response rate over interferon alfa-2a alone or in combination with Ribavirin.

Download detailed advice21KB (PDF)

Download

Medicine details

Medicine name:
Pegylated interferon alfa-2a (Pegasys®)
SMC ID:
10/02
Indication:
Chronic hepatitis C
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Restricted
Date advice published
06 September 2002